An ongoing phase III, double-blind, placebo-controlled trial aims to evaluate the efficacy and safety of the anti-IL17 mAb secukinumab in combination with standard of care treatment in patients with active lupus nephritis (39). The gene discussed is IL17A; the disease is lupus nephritis.